Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
about
Improved hemostasis in hemophilia mice by means of an engineered factor Va mutantPlatelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombinEngineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.Novel therapeutic approaches for haemophilia.Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.Bioengineered factor Xa as a potential new strategy for hemophilia therapy.
P2860
Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Peptidomimetic inhibitors for ...... ons for hemophilia management.
@en
Peptidomimetic inhibitors for ...... ons for hemophilia management.
@nl
type
label
Peptidomimetic inhibitors for ...... ons for hemophilia management.
@en
Peptidomimetic inhibitors for ...... ons for hemophilia management.
@nl
prefLabel
Peptidomimetic inhibitors for ...... ons for hemophilia management.
@en
Peptidomimetic inhibitors for ...... ons for hemophilia management.
@nl
P2093
P2860
P1476
Peptidomimetic inhibitors for ...... ons for hemophilia management.
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2006.02226.X
P577
2006-11-01T00:00:00Z